Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival

Cancer Investigation

Volumn 26, Issue 8, 2008, Pages 852-859

  Casneuf, Veerle F ^a   Fonteyne, Philippe ^a   Van Damme, Nancy ^a   Demetter, Pieter ^b   Pauwels, Patrick ^a   De Hemptinne, Bernard ^a   De Vos, Martine ^a   Van De Wiele, Christophe ^a   Peeters, Marc ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Bcl 2; p53; Pancreatic cancer; SGLT1; Survival

Indexed keywords

GEMCITABINE; PROTEIN BCL 2; PROTEIN P53; SODIUM GLUCOSE COTRANSPORTER 1;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PANCREATECTOMY; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SODIUM-GLUCOSE TRANSPORTER 1; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 53949106060     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900801956363     Document Type: Article

References (34)

1. Jemal, A.; Murray, T.; Ward, E.; Samuels, A.; Tiwari, R.C.; Ghafoor, A.; Feuer, E.J.; Thun, M.J. Cancer statistics 2005. CA Cancer J Clin 2005, 55, 10-30.
2. Wray, C.J.; Ahmad, S.A.; Matthews, J.B.; Lowy, A.M. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology 2005, 128, 1626-1641.
3. Casneuf, V.F.; Delrue, L.; Kelles, A.; Van Damme, N.; Van Huysse, J.; Berrevoet, F.; De Vos, M.; Duyck, P.; Peeters, M. Is Combined 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography superior to Positron Emission Tomography or Computed Tomography alone for diagnosis, staging and restaging of pancreatic lesions? Acta Gastroenterol Belg 2007, 70, 331-338.
4. Wood, I.S.; Trayhurn, P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003, 89, 3-9.
5. Crone, C. The diffusion of some non-electrolytes from blood to brain tissue. Acta Physiol Scand Suppl 1960, 175, 33-34.
6. Hediger, M.A.; Coady, M.J.; Ikeda, T.S.; Wright, E.M. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature 1987, 330, 379-381.
7. Díez-Sampedro, A.; Eskandari, S.; Wright, E.M.; Hirayama, B.A. Na+-to-sugar stoichiometry of SGLT3. Am J Physiol Renal Physiol 2001, 280, F278-F282.
8. Mahraoui, L.; Rodolosse, A.; Barbat, A.; Dussaulx, E.; Zweibaum, A.; Rousset, M.; Brot-Laroche, E. Presence and differential expression of SGLT1, GLUT1, GLUT2, GLUT3 and GLUT5 hexose-transporter mRNAs in Caco-2 cell clones in relation to cell growth and glucose consumption. Biochem J 1994, 15, 298, Pt 3, 629-633.
9. Blais, A. Expression of Na(+)-coupled sugar transport in HT-29 cells: modulation by glucose. Am J Physiol 1991, 260, C1245-1252.
10. Ishikawa, N.; Oguri, T.; Isobe, T.; Fujitaka, K.; Kohno, N. SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res 2001, 92, 874-879.
11. Helmke, B.; Reisser, C.; Idzkoe, M.; Dyckhoff, G.; Herold-Mende, C. Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck. Oral Oncology 2004, 40, 28-35.
12. Muñoz-Pinedo, C.; Ruiz-Ruiz, C.; Ruiz de Almodóvar, C.; Palacios, C.; López-Rivas, A. Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing. J Biol Chem 2003, 278, (15), 12759-12768.
13. Reed, J.C.; Miyashita, T.; Takayama, S.; Wang, H.G.; Sato, T.; Krajewski, S.; Aime-Sempe, C.; Bodrug, S.; Kitada, S.; Hanada, M. Bcl-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996, 60, 23-32.
14. Sun, C.Y.; Wang, B.L.; Hu, C.Q.; Peng, R.Y.; Gao, Y.B.; Gu, Q.Y.; Wang, D.W. Expression of the bcl-2 gene and its significance in human pancreatic carcinoma. Hepatobiliary Pancreat Dis Int 2002, 1, 306-308.
15. Vogelstein, B. Cancer: a deadly inheritance. Nature 1990, 348, 681-682.
16. Munro, A.J.; Lain, S.; Lane, D.P. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005, 92, 434-444.
17. Kern, S.E.; Pietenpol, J.A.; Thiagalingam, S.; Seymour, A.; Kinzler, K.W.; Vogelstein, B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1990, 256, 827-830.
18. Sobin, L.H.; Wittekind, C.; UICC, International Union against cancer. TNM classification of malignant tumors, Sixth edition. Wiley-Liss: New York, 2002, 93-96.
19. Cao, X.; Fang, L.; Gibbs, S.; Huang, Y.; Dai, Z.; Wen, P.; Zheng, X.; Sadee, W.; Sun, D. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol 2007, 59 (4), 495-505.
20. Bissonnette, P.; Gagné, H.; Coady, M.J.; Benabdallah, K.; Lapointe, J.Y.; Berteloot, A. Kinetic separation and characterization of three sugar transport modes in Caco-2 cells. Am J Physiol 1996, 270, G833-G843.
21. Delezay, O.; Verrier, B.; Mabrouk, K.; van Rietschoten, J.; Fantini, J.; Mauchamp, J.; Gerard, C. Characterization of an electrogenic sodium/glucose cotransporter in a human colon epithelial cell line. J Cell Physiol 1995, 163, 120-128.
22. Nelson, J.A.; Falk, RE. The efficacy of phloridzin and phloretin on tumor cell growth. Anticancer Res 1993, 13, 2287-2292.
23. Halicka, H.D.; Ardelt, B.; Li, X.; Melamed, M.M.; Darzynkiewicz, Z. 2-Deoxy-D-glucose enhances sensitivity of human histiocytic lymphoma U937 cells to apoptosis induced by tumor necrosis factor. Cancer Res 1995, 15, 444-449.
24. Briasoulis, E.; Judson, I.; Pavlidis, N.; Beale, P.; Wanders, J.; Groot, Y.; Veerman, G.; Schuessler, M.; Niebch, G.; Siamopoulos, K.; Tzamakou, E.; Rammou, D.; Wolf, L.; Walker, R.; Hanauske, A. Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. J Clin Oncol 2000, 18, 3535-3544.
25. Hockenbery, D.M.; Zutter, M.; Hickey, W.; Nahm, M.; Korsmeyer, S.J. BCL-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991, 88 (16), 6961-6965.
26. Sinicrope, F.A.; Evans, D.B.; Leach, S.D.; Cleary, K.R.; Fenoglio, C.J.; Lee, J.J.; Abbruzzese, J.L. Bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res 1996, 2 (12), 2015-2022.
27. Hu, Y.X.; Watanabe, H.; Ohtsubo, K.; Yamaguchi, Y.; Ha, A.; Motoo, Y.; Okai, T.; Sawabu, N. Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma. Br J Cancer 1999, 80, 1075-1079.
28. Shim, H.; Chun, Y.S.; Lewis, B.C.; Dang, C.V. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci USA 1998, 95, 1511-1516.
29. Sinicrope, F.A.; Hart, J.; Michelassi, F.M.; Lee, J. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res 1995, 1, 1103-1110.
30. Herod, J.J.; Eliopoulos, A.G.; Warwick, J.; Niedobitek, G.; Young, L.S.; Kerr, D.J. The prognostic significance of bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996, 56, 2178-2184.
31. Huang, Z.; Lei, X.; Zhong, M.; Zhu, B.; Tang, S.; Liao, D. Bcl-2 Small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDP cell to cisplatin and diallyl disulfide. Acta Biochim Biophys Sin (Shanghai) 2007, 39, 835-843.
32. Lei, X.Y.; Zhong, M.; Feng, L.F.; Zhu, B.Y.; Tang, S.S.; Liao, D.F. SiRNA-mediated Bcl-2 and Bcl-xl gene silencing sensitizes human hepatoblastoma cells to chemotherapeutic drugs. Clin Exp Pharmacol Physiol 2007, 34, 450-456.
33. Ocker, M.; Neureiter, D.; Lueders, M.; Zopf, S.; Ganslmayer, M.; Hahn, E.G.; Herold, C.; Schuppan, D. Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut 2005, 54 (9), 1298-1308.
34. Okamoto, K.; Ocker, M.; Neureiter, D.; Dietze, O.; Zopf, S.; Hahn, E.G.; Herold, C. Bcl-2-specific siRNAs restore gemcitabine sensitivity in human pancreatic cancer cells. J Cell Mol Med 2007, 11 (2), 349-361.